Driehaus Capital Management LLC Blueprint Medicines Corp Transaction History

Driehaus Capital Management LLC

$10.2 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$85.18 - $108.78 $15.3 Million - $19.6 Million	180,043 Added 101.03%	358,255 $38.6 Million
Q1 2024 May 15, 2024	BUY	$73.17 - $99.79 $13 Million - $17.8 Million	178,212 New	178,212 $16.9 Million
Q2 2022 Aug 15, 2022	SELL	$45.23 - $70.15 $6.05 Million - $9.38 Million	-133,690 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$54.1 - $110.08 $9.84 Million - $20 Million	-181,949 Reduced 57.64%	133,690 $8.54 Million
Q4 2021 Feb 14, 2022	BUY	$94.25 - $115.99 $13.2 Million - $16.3 Million	140,480 Added 80.2%	315,639 $33.8 Million
Q3 2021 Nov 15, 2021	BUY	$80.98 - $109.47 $4.21 Million - $5.69 Million	51,961 Added 42.18%	175,159 $18 Million
Q2 2021 Aug 16, 2021	SELL	$82.78 - $101.0 $661,908 - $807,596	-7,996 Reduced 6.09%	123,198 $10.8 Million
Q1 2021 May 17, 2021	BUY	$90.71 - $108.28 $403,659 - $481,846	4,450 Added 3.51%	131,194 $12.8 Million
Q4 2020 Feb 16, 2021	SELL	$92.08 - $124.48 $421,358 - $569,620	-4,576 Reduced 3.48%	126,744 $14.2 Million
Q3 2020 Nov 16, 2020	BUY	$66.45 - $92.7 $3.76 Million - $5.25 Million	56,586 Added 75.72%	131,320 $12.2 Million
Q2 2020 Aug 14, 2020	BUY	$57.09 - $79.27 $1.8 Million - $2.49 Million	31,468 Added 72.73%	74,734 $5.83 Million
Q1 2020 May 15, 2020	SELL	$48.11 - $82.22 $819,650 - $1.4 Million	-17,037 Reduced 28.25%	43,266 $2.53 Million
Q4 2019 Feb 12, 2020	SELL	$66.73 - $82.59 $956,374 - $1.18 Million	-14,332 Reduced 19.2%	60,303 $4.83 Million
Q3 2019 Nov 14, 2019	SELL	$72.9 - $101.41 $2.86 Million - $3.98 Million	-39,239 Reduced 34.46%	74,635 $5.48 Million
Q2 2019 Aug 14, 2019	SELL	$73.54 - $97.8 $1.06 Million - $1.41 Million	-14,457 Reduced 11.27%	113,874 $10.7 Million
Q1 2019 May 15, 2019	BUY	$48.7 - $86.6 $5.32 Million - $9.47 Million	109,336 Added 575.6%	128,331 $10.3 Million
Q3 2018 Nov 14, 2018	SELL	$58.91 - $78.32 $7.02 Million - $9.33 Million	-119,098 Reduced 86.24%	18,995 $1.48 Million
Q2 2018 Aug 14, 2018	SELL	$60.96 - $101.18 $9.64 Million - $16 Million	-158,196 Reduced 53.39%	138,093 $8.77 Million
Q1 2018 May 15, 2018	BUY	$73.28 - $102.95 $1.12 Million - $1.57 Million	15,229 Added 5.42%	296,289 $27.2 Million
Q4 2017 Feb 14, 2018	BUY	$62.91 - $88.32 $6 Million - $8.42 Million	95,325 Added 51.32%	281,060 $21.2 Million
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $7.87 Million - $12.9 Million	185,735	185,735 $12.9 Million

Others Institutions Holding BPMC

# of Institutions

350

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

Vanguard Group Inc Valley Forge, PA

6.68M
Shares

$632 Million
0.01% of portfolio
Black Rock Inc. New York, NY

6.65M
Shares

$629 Million
0.02% of portfolio
Price T Rowe Associates Inc Baltimore, MD

5.39M
Shares

$510 Million
0.06% of portfolio
Wellington Management Group LLP Boston, MA

3.96M
Shares

$375 Million
0.07% of portfolio
State Street Corp Boston, MA

2.77M
Shares

$262 Million
0.01% of portfolio

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.65B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Driehaus Capital Management LLC with notifications on news.

Account